-+ 0.00%
-+ 0.00%
-+ 0.00%

DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia

Benzinga·03/05/2026 12:38:08
Listen to the news

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE). This regulatory clearance enables DiaMedica to initiate its Phase 2 study of DM199 in early-onset preeclampsia. The Company plans to initiate the trial in 2026 and expand into the United States and United Kingdom as regulatory clearances are obtained.